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Abstract
 .Exposure to various combinations of cytokines and lipopolysaccharide LPS has been reported to increase NO
 .production in vascular endothelial cells. The molecular entity of the newly expressed nitric oxide synthase NOS in
endothelial cells, however, has not yet been examined in detail. In this report, we carried out biochemical characterizations
 .  .and molecular identification of NOS isoform s expressed in cytokinerLPS-treated bovine aortic endothelial cells BAEC .
 .The increased NOS activity in tumor necrosis factor-a TNF-a rLPS-treated BAEC was localized mainly in the cytosolic
2q  .fraction and Ca -independent, whereas that in interferon-a ,b IFN-a ,b rLPS-treated BAEC was preferentially in the
2q  .membrane fraction and Ca -dependent, suggesting that TNF-arLPS increased an inducible NOS iNOS -like activity, and
 .IFN-a ,brLPS increased an endothelial constitutive NOS ecNOS -like activity. Correspondingly, the different responses to
the cytokinerLPS pretreatment were demonstrated in semi-quantitative reverse transcription-polymerase chain reaction
 .RT-PCR using primers specific for iNOS or ecNOS, that is, TNF-arLPS elicited the expression of iNOS mRNA whereas
IFN-a ,brLPS increased that of ecNOS mRNA. A nuclear run-on transcription assay and an inhibition experiment by
actinomycin D indicated that the apparent increase of ecNOS in the IFN-a ,brLPS-treated BAEC was at least in part
ascribed to the transcriptional activation. The nucleotide sequences of the amplified PCR products in TNF-arLPS- and
IFN-a ,brLPS-treated BAEC were 93% and 99% identical to the corresponding regions of human hepatocyte iNOS and
bovine ecNOS, respectively. These findings indicated that, in cytokinerLPS-treated BAEC, two NOS isoforms whose
molecular natures were closely homologous to the conventional isoforms of iNOS and ecNOS were differently induced in
response to distinct inflammatory stimuli.
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1. Introduction
 .Nitric oxide NO produced by endothelial cells
plays a crucial role in the regulation of vascular tone,
w xplatelet aggregation and leukocyte adhesion 1 . The
 .nitric oxide synthase NOS isolated to date are
grouped into two isoforms; one is constitutively ex-
 .pressed NOS cNOS which includes two subtypes,
 . w xendothelial cell NOS ecNOS 2–5 and neuronal
 . w xNOS nNOS 6 , and the other is cytokinerLPS-in-
 . w xducible NOS iNOS 7–9 . ecNOS exhibits
2q w xCa rcalmodulin-dependency 10 and exists as a
w xmembrane-bound enzyme 11 , whereas iNOS has no
apparent Ca2qrcalmodulin dependency and exists as
w xa soluble form 12 .
Recently, some cytokines andror lipopolysaccha-
 .ride LPS were reported to enhance NO production
w xin vascular endothelial cells 13–17 . The increase in
NOS activity was preceded by a several hour lag-
phase and was inhibited by both transcription and
translation inhibitors, indicating that the increase was
mediated through de novo synthesis of NOS enzyme
in cytokinerLPS-treated endothelial cells. Indeed, an
iNOS-like mRNA and protein were detected in thus
treated endothelial cells by Northern blot and im-
w xmunoblot analyses 17,18 . Furthermore, although the
newly-synthesized NOS in the cytokinerLPS-treated
cells has generally been considered as the expression
of an inducible isoform of NOS, accumulating evi-
dences showed that even the ecNOS could be regu-
lated at the expression level by certain stimuli such as
w x w xshear stress 5 , estrogen 19 , lysophosphatidyl
w x w x w xcholine 20 , oxidized LDL 21 and hypoxia 22 .
Moreover, recently, NOSs whose subcellular localiza-
tions were different from those of the conventional
w xones were reported 23 . These findings raise the
possibility that the increase of NOS activity observed
in cytokinerLPS-treated endothelial cells could be
attributed to the expression of functionally and struc-
 .turally novel isoform s of iNOS andror ecNOS.
In the present report, to determine NOS isoforms
responsible for cytokinerLPS-mediated NO produc-
tion in endothelial cells, we used a combined ap-
proach including biochemical characterization and
molecular identification of the newly-expressed
 .NOS s . The results presented here indicated the
existence of two NOS isoforms inducibly expressed
in endothelial cells under different controls of distinct
inflammatory stimuli.
2. Materials and methods
2.1. Preparation of bo˝ine aortic endothelial cells
 .Bovine aortic endothelial cells BAEC were har-
vested from bovine thoracic aorta obtained from a
local slaughterhouse and cultured in RPMI 1640
medium supplemented with 10% FCS as described
w xby Kitazono et al. 24 . The identity of endothelial
cells was verified by their characteristic morphology
and the presence of factor VIII-associated antigen.
The number of living BAEC was estimated from
cell-associated lactate dehydrogenase activity in each
experiment. The monolayers of BAEC after reaching
confluency were incubated for the indicated periods
withrwithout cytokinerLPS in Eagle’s MEM
 .without phenol red; Nissui, Japan containing 0.5%
FCS. The cytokines and LPS used were as follows;
recombinant human interferon-a IFN-a ; Takeda
.Pharmaceuticals Co., Japan , recombinant human in-
terferon-b IFN-b ; Daiichi Pharmaceuticals Co.,
.Japan , recombinant human tumor necrosis factor-a
 . TNF-a ; Genzyme , Lipopolysaccharide LPS; E.
.coli, Serotype 0127:B8, Sigma . Endothelial cells at
up to passage 10 were used for the experiments.
(2.2. Determination of nitric oxide production metHb
)assay
Nitric oxide production in intact endothelial cell
monolayers was measured spectrophotometrically
 .Beckman DU 640 spectrophotometer by the conver-
 .sion of oxyhemoglobin oxyHb to methemoglobin
 . w xmetHb essentially as described by Hevel et al. 25 .
Cytokine-pretreated cells were incubated in NO de-
wtection medium Hepes-buffered Hanks balanced salt
 .solution containing 5 mM oxyHb, 5% vrv FCS, 10
xmgrml SOD and 100 mM L-arginine for the indi-
cated periods. The medium was collected and cen-
trifuged at 2500=g for 5 min. The absorbance at
401 nm and 411 nm of the supernatant was measured
to determine the concentration of metHb using an
y1 y1 w xextinction coefficient of 60 mM Pcm 25 . The
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medium collected immediately after pouring onto the
cells was used for the 0-time control. NOS activity
was calculated from the metHb formation assuming
that the nitric oxide converted the equal amount of
oxyHb to metHb. The value obtained in the presence
G  .of 1 mM N -monomethyl-L-arginine L-NMMA in-
stead of L-arginine was subtracted from all data as
nonspecific metHb formation. Nitric oxide production
of BAEC measured by the metHb formation in-
creased almost linearly up to 3 h under these condi-
tions.
2.3. Subcellular fractionation
Subcellular fractionation was carried out as de-
w xscribed by Hecker et al. 26 with minor modifica-
tions. Cells were disrupted in homogenization buffer
w  .50 mM TrisrHCl buffer pH 7.4 containing 1.15%
 .wrv KCl, 1 mM EDTA, 5 mM glucose, 0.1 mM
DL-dithiothreitol, 200 Urml superoxide dismutase, 5
mgrml chymostatin, 10 mgrml leupeptin, antipain
and pepstatin, and 20 mM p-amidino-phenylmethyl-
xsulfonyl fluoride by five freeze-thaw cycles in liquid
nitrogen. The homogenate was centrifuged at 1000=
g for 10 min at 48C and the supernatant was recen-
trifuged at 200 000=g for 30 min at 48C. The
resultant pellet was resuspended in suspending buffer
w  .50 mM TrisrHCl buffer pH 7.4 containing 10%
 .vrv glycerol, 0.1 mM EDTA, 0.1 mM dithio-
xthreitol and protease inhibitors as described above
and was used as the membrane fraction. The super-
natant was used as the cytosolic fraction.
2.4. Determination of NO synthase acti˝ity in subcel-
( )lular fractions citrulline assay
NOS activity in subcellular fractions was measured
w14 x w14 xby the conversion of L- C arginine to L- C citrul-
w xline as described by Hecker et al. 26 . Briefly,
cytosolic or membrane fraction prepared from cy-
tokinerLPS-treated BAEC was incubated at 378C for
30 min in reaction mixtures containing 50 mM Hepes,
1 mM dithiothreitol, 1 mM CaCl or EGTA, 0.1 mM2
tetrahydrobiopterin, 1 mM NADPH, 10 mM flavin
adenine dinucleotide, 10 mgrml calmodulin and 1.68
w14 x  .mM L- C arginine 292 mCirmmol; Amersham .
To investigate the effect of actinomycin D, we also
performed the experiment with membrane fraction
derived from BAEC which were pretreated with acti-
 .nomycin D 0.2 mgrml for 2 h before addition of
cytokinerLPS. The incubation was terminated by
addition of ice cold stop solution 100 mM Hepes,
.pH 5.5, 10 mM EDTA, 2 mM EGTA containing
Dowex AG50 W-X8 resin and centrifuged. The
w14 xC citrulline in the supernatant was quantitated with
emulsifying scintillator cocktail Clear-Sol Nacarai
.Tesque, Japan in a liquid scintillation counter. The
value obtained in the presence of 1 mM N G-mono-
methyl-L-arginine was used as a blank and subtracted
from all data. Citrulline formation of BAEC subcellu-
lar fractions increased almost linearly up to 30 min
under these conditions.
2.5. Re˝erse transcription-polymerase chain reaction
( )RT-PCR
Semiquantitative RT-PCR was performed to iden-
tify and quantitate iNOS and ecNOS mRNAs in the
cytokinerLPS-treated BAEC essentially as described
w xby North et al. 27 . Total RNA was isolated from
confluent cultured cells using TRIzol Reagent
 .Gibco-BRL based on the method reported by
w xChomczynski and Sacchi 28 . RT reactions were
 .carried out with isolated total RNA 0.5 mg and 100
 .units of M-MLV reverse transcriptase GIBCO-BRL
according to the manufacturer’s recommended proto-
col at 378C for 60 min and stopped by heating at
988C for 10 min. The reverse transcribed cDNA
products were amplified in the presence of 1 mM of
each primer, 0.2 mM of dNTPs and 1.25 U of Taq
DNA polymerase in a DNA thermal cycler PJ2000
 .Perkin-Elmer . The conditions for each cycle were
set as 948C for 45 s, 608C for 45 s and 728C for 2
min. The following gene-specific primers were used:
w x Xfor iNOS 9 , 5 -AGGGTGGAAGCGGT -
X  . XAACAAAGG-3 bases 699 to 720, sense and 5 -
X ATCTGGTAGCCAGCATAGCGGA-3 bases 1000
.to 1021, antisense , amplifying a 323 bp product; for
w x XecNOS 16 , 5 -AGAAAGGAGTCCAGCAACA-
X  . XCAG-3 bases 1951 to 1972, sense and 5 -GCTT-
X TGCAGATTTTCCACC GAG-3 bases 2355 to
.2376, antisense , amplifying a 426 bp product. Each
primer set yielded a single PCR product of the pre-
dicted size. The identity of the PCR products was
confirmed by direct cycle sequencing. RT-PCR was
also performed for the housekeeping gene b-actin or
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Fig. 1. Linearity of semiquantitative RT-PCR. Semiquantitative
RT-PCR showed a linear relationship between the amount of
total RNA in the RT reaction and that of PCR products. The
correlation coefficients for ecNOS, iNOS and b-actin products
were 0.997, 0.971 and 0.988, respectively.
 .glyceraldehyde 3-phosphate dehydrogenase GAPDH
as a control for the amount of RNA used in the RT
reaction. A negative control, omitting reverse tran-
scriptase, was also performed to exclude the possibil-
ity of the amplification from contaminated genomic
DNA.
2.6. Densitometric analysis of PCR products
The PCR products were separated on a 2% agarose
gel containing 0.01% ethidium bromide and the in-
tensity of the stained bands was quantitated by den-
sitometric analysis using the public domain computer
program ‘NIH Image’ Wayne Rasband, NIH, Re-
.search Service Branch, NIMH, USA . Linear rela-
tionships were observed between the quantity of RNA
subjected to RT reaction and the amount of amplified
PCR product under the PCR conditions used for
 . iNOS and ecNOS 40 cycles , and for b-actin 35
.  .cycles Fig. 1 . The abundance of iNOS and ecNOS
PCR products were corrected for that of b-actin or
GAPDH, which gave essentially the same results.
2.7. Nuclear run-on assay
Nuclei isolation and run-on transcriptional assays
w xwere performed as described by Kubo et al. 29 with
minor modifications. Briefly, about 5=107 nuclei
isolated from IFN-a ,brLPS-treated and untreated
w 32 xBAEC were incubated with a- P UTP at 308C for
30 min and the nascent 32P-labeled run-on RNA was
isolated. Plasmids containing the cDNA inserts for
ecNOS or b-actin were prepared from the PCR prod-
 .ucts using TA cloning kit Invitrogen . The plasmids
with the insert DNAs were linearized, denatured and
q  .slot-blotted onto Hybond N membrane Amersham ,
and then hybridized with the 32P-labeled RNA. As a
negative control, we performed the same experiment
for the plasmids without any inserts. The radioactiv-
ity in each slot was determined with a bioimaging
 .analyzer BAS2000; Fuji Film Co., Japan .
2.8. Nucleotide sequence determination
The PCR products were size-fractionated on a
low-melting agarose and their DNAs were isolated
from the excised gels. The nucleotide sequences of
the isolated DNAs were determined by direct cycle
sequencing with Dye Deoxy Terminator kit using a
DNA sequencer model 373 A Applied Biosystems,
.USA according to the manufacturer’s recommended
protocol.
2.9. Statistical analysis
Results were expressed as means"S.E.M. Statis-
tical analysis was performed using Student’s t-test.
Differences were considered statistically significant
for P-0.05.
3. Results
3.1. NO production in BAEC pretreated with cy-
tokinesrLPS
NO producing activity of BAEC pretreated with
either TNF-arLPS or IFN-a ,brLPS increased in a
 .time-dependent manner Fig. 2 . The NOS activity of
BAEC treated in either way stayed at the control
level up to 8 h after stimulation with cytokinesrLPS,
and then increased by several folds along with pro-
longed incubation for 24–48 h. The observed time
lag suggested that the increase was due to the de
novo synthesis of NOS rather than the activation of
NOS already present in the cells. The detected NO
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Fig. 2. Time-dependent change in nitric oxide production in
BAEC treated with TNF-arLPS or IFN-a ,brLPS. Nitric oxide
production was measured by the conversion of oxyHb to metHb
as described in Section 2. BAEC was treated with TNF-a 1000
.  .  .  .Urml and LPS 50 mgrml ’ or IFN-a ,b 200 Urml each
 .and LPS B for the indicated periods before incubation in nitric
oxide detection medium. Data points represent means"S.E.M. of
determinations from 3 experiments.
producing activity was inhibited by L-arginine analogs
G  .such as N -monomethyl-L-arginine L-NMMA and
G  .N -nitro-L-arginine-methyl-ester L-NAME , indicat-
 . ing it was mediated by NO synthase NOS data not
.shown .
3.2. Ca2q-dependency and subcellular localization of
NOS acti˝ity in cytokinesrLPS-treated BAEC
To determine NOS isoform responsible for cy-
tokinerLPS-induced NO production, we investigated
Ca2q-dependency and subcellular localization of NOS
activity in cytokinerLPS-treated BAEC. NOS activ-
ity was determined as the L-NMMA-inhibitable con-
w14 x w14 xversion of L- C arginine to L- C citrulline using
cell lysates supplemented with tetrahydrobiopterin.
As shown in Fig. 3, the increased NOS activity in
TNF-arLPS-treated BAEC was localized mainly in
the cytosolic fraction and Ca2q-independent, whereas
that in IFN-a ,brLPS-treated BAEC was localized
preferentially in the membrane fraction and Ca2q-de-
pendent, indicating that TNF-arLPS stimulated
iNOS-like activity, while IFN-a ,brLPS increased
ecNOS-like activity.
3.3. ecNOS and iNOS mRNA expression in cytokines
rLPS-treated BAEC
Different responses of NOS activity to
cytokinerLPS pretreatment observed in BAEC were
further confirmed by RT-PCR analysis of the mRNA
expression. Primers specific for iNOS yielded a sin-
gle PCR product of the predicted size only in TNF-
 .arLPS-treated cells Fig. 4 . Increasing the number
 .of PCR cycles up to 45 still did not yield any
detectable bands in extracts from control or IFN-
a ,brLPS-treated cells. The amount of iNOS mRNA
in TNF-arLPS-treated cells increased gradually and
reached a maximal level at 12 h after the activation
 .Fig. 5 .
In contrast, when primers specific for ecNOS were
used, PCR products of the predicted size were de-
tected all in the control, TNF-arLPS- and IFN-
a ,brLPS-treated BAEC, but that of the IFN-
Fig. 3. Distribution of Ca2q-dependent or -independent nitric
oxide synthase activity in subcellular fractions of unstimulated
and cytokinerLPS-induced BAEC. NOS activity in the cytosolic
and membrane fractions were determined by monitoring the
G w14 xN -monomethyl-L-arginine-sensitive conversion of L- C argi-
w14 xnine to L- C citrulline per min in the presence of 1 mM CaCl2
 .or EGTA ns2–3 . After pretreatment with cytokinerLPS or
vehicle for 24 h, BAEC homogenates were subfractionated as
described in Section 2. The data are expressed as means"S.E.M.
 .ns3 . The value obtained in the presence of 1 mM L-NMMA
was subtracted from all data as nonspecific counts. )P -0.05
and ))P -0.01, compared with each indicated value, were
statistically significant.
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a ,brLPS-treated cells showed the highest intensity
 .Fig. 4 . The increase in abundance of ecNOS mRNA
in IFN-a ,brLPS-treated cells was more evident in
the time-dependent change of the PCR product. The
amount of the ecNOS mRNA reached a maximal
level at 3 h and then decreased gradually to the initial
 .level at 12 to 24 h Fig. 6 . The amount of ecNOS
mRNA in control and TNF-arLPS-treated cells re-
mained almost constant during this period data not
.shown .
3.4. Transcription of ecNOS mRNA in IFN-a ,br
LPS-treated BAEC
We performed two sets of experiments to investi-
gate the mechanism of the apparent induction of
ecNOS in the IFN-a ,brLPS-treated BAEC. First,
we investigated the effect of actinomycin D on the
increase of the Ca2q-dependent, membrane-bound
NOS activity after IFN-a ,brLPS stimulation. As
shown in Fig. 7, actinomycin D suppressed the IFN-
a ,brLPS-mediated increase of the NOS activity to
the control level. Second, a nuclear run-on transcrip-
tional assay was performed with nuclei isolated from
Fig. 4. The RT-PCR detection of the ecNOS and iNOS mRNA
expression in cytokinerLPS-treated BAEC. The expression of
ecNOS and iNOS mRNAs in BAEC treated for 12 h in the
 .  .absence or presence of TNF-a 1000 Urml , IFN-a 200 Urml ,
  .IFN-b 200 unitsrml and LPS 50 mgrml was detected by
semiquantitative RT-PCR. PCR reactions were carried out with
 .  .ecNOS lanes 1–3 or iNOS-specific primers lanes 4–6 using
 .equivalent amounts of total RNA isolated from control lane 1,4 ,
 . TNF-arLPS-treated lane 2,5 and IFN-a ,brLPS-treated lane
.3,6 BAEC as described in Section 2. The ecNOS PCR product
was detected as a 426 bp band and that of iNOS as a 323 bp
band. The RT-PCR product from activated mouse macrophages is
shown in lane 7 as a positive control. Size marker is shown on
 .the left side f =174rHincII digest . The results shown are
from a single representative of three independent experiments.
Fig. 5. Time-dependent changes in iNOS mRNA expression in
TNF-arLPS-treated BAEC. iNOS mRNA expression was de-
tected by semiquantitative RT-PCR as described in Section 2.
Abundance of iNOS PCR product corrected for that of b-actin is
expressed as a percentage of the maximum level at 12 h defined
.as 100% . Upper: a typical photograph of agarose electrophoresis
of the PCR products was shown from a single representative of
three independent experiments. Lower: quantitative data of den-
sitometric analysis of the stained bands from three independent
 .experiments were shown as means"S.E.M. ns4 .
the IFN-a ,brLPS-treated BAEC. By densitometry,
the ratio of nascent ecNOS RNA transcripts to b-actin
was 0.83"0.05 in control cells and increased to
3.78"0.25 after the IFN-a ,brLPS stimulation Fig.
.8 . These results indicated that the observed increase
of the activity and the mRNA level of ecNOS was
ascribed at least in part to the transcriptional activa-
tion of ecNOS expression.
3.5. Nucleotide sequence of the PCR products
The nucleotide sequences of the PCR products
amplified from cytokinerLPS-pretreated BAEC were
determined by direct cycle sequencing to verify the
NOS isoforms. The PCR product amplified with the
iNOS-specific primers in TNF-arLPS- pretreated
BAEC showed 93%, 87% and 87% identity at the
nucleotide level, and 98%, 91% and 92% identity at
the amino acid level, with the corresponding region
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Fig. 6. Time-dependent changes in ecNOS mRNA expression in
IFN-arIFN-brLPS-treated BAEC. ecNOS mRNA expression
was detected by semiquantitative RT-PCR as described in Sec-
tion 2. Abundance of ecNOS PCR product corrected for that of
b-actin is expressed as a percentage of the maximum level at 3 h
 .defined as 100% . Upper: a typical photograph of agarose
electrophoresis of the PCR products was shown from a single
representative of three independent experiments. Lower: quantita-
tive data of densitometric analysis of the stained bands from three
 .independent experiments were shown as means"S.E.M. ns4 .
Fig. 7. Effect of actinomycin D on membrane-bound NOS activ-
ity in BAEC stimulated with IFN-a ,brLPS. NOS activity in the
membrane fraction was determined by monitoring the N G-mono-
w14 xmethyl-L-arginine-sensitive conversion of L- C arginine to L-
w14 x  .C citrulline per min ns3 . BAEC was pretreated with
 .actinomycin D 0.2 mgrml or vehicle for 2 h before addition of
IFN-a ,brLPS. The value obtained in the presence of 1 mM
L-NMMA was subtracted from all data as nonspecific counts.
Fig. 8. Nuclear run-on transcription assay for ecNOS gene in
IFN-a ,brLPS-treated BAEC. Nuclei obtained from BAEC
treated with vehicle or IFN-a ,brLPS were used to synthesize
32P-labeled RNA transcripts, which was hybridized to a filter slot
blotted with plasmids containing ecNOS or b-actin cDNA in-
serts. Abundance of ecNOS transcripts corrected for that of
b-actin transcripts was shown lower.
w xof iNOS cDNAs of human hepatocyte 9 , rat vascu-
w x w xlar smooth muscle cell 7 and mouse macrophage 8 ,
 .respectively Fig. 9 , indicating that TNF-arLPS
Fig. 9. Deduced amino acid sequence of iNOS in TNF-arLPS-
treated BAEC, aligned with those of iNOS isoforms from human
w x w xhepatocyte 9 , rat vascular smooth muscle cell 7 and mouse
w xmacrophage 8 . The amino acid residues identical with those of
 .the BAEC iNOS are indicated by dashes – . Substituted residues
are shown as single capital letter code. The amino acid residues
conserved in all the molecules from the four different sources are
indicated by dot. The serine residue at a phosphorylation site by
cAMP-dependent protein kinase was underlined.
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caused BAEC to express an inducible NOS isoform
quite similar to the conventional one.
On the other hand, the sequences of the PCR
products amplified with the ecNOS-specific primers
in control and cytokinerLPS-pretreated BAEC exhib-
ited more than 99% identity at the nucleotide level,
and matched precisely at the amino acid level, with
the corresponding region of the published sequence
w xof bovine ecNOS 16 . The increase of the amplified
band of the IFN-a ,brLPS-pretreated BAEC, there-
fore, was attributed to the ecNOS mRNA.
4. Discussion
Nitric oxide synthase in endothelial cells has been
considered to be expressed constitutively and its ac-
tivity to be regulated by Ca2q-mobilizing vasoactive
substances in a rapid and transient manner. Recently,
w xhowever, several lines of evidence 13–18 indicated
that the treatment with cytokines andror LPS en-
hanced the NOS activity in several kinds of endothe-
w xlial cells as they did in macrophages 30 and hepato-
w x  w x.cytes 31 for review, see Ref. 32 . In fact, a certain
isoform of inducible NOS was demonstrated to be
co-expressed with ecNOS in cytokinerLPS-treated
endothelial cells. Moreover, even the expression of
ecNOS was reported to be enhanced by various extra-
cellular stimuli. These findings suggested that not
only iNOS but also ecNOS, could be regulated at the
expression level in endothelial cells, which led us to
examine the expression pattern of NOS isoforms in
cytokinerLPS-treated endothelial cells.
The present results demonstrated that BAEC treated
with TNF-arLPS elicited the Ca2q-independent solu-
ble NOS activity, and simultaneously expressed an
iNOS-like mRNA whose nucleotide sequence shared
high homology with the published sequences of iN-
OSs from various cell types. These results indicated
that TNF-arLPS caused BAEC to express a certain
iNOS isoform which, in respect of biochemical prop-
erties and molecular structure, was identical or at
least quite similar to the previously described ones.
There are conflicting data about the number of
w xiNOS genes. Chartrain et al. 33 screened a human
genomic library using both the murine macrophage
and human hepatocyte iNOS cDNA probes, and iso-
lated positive clones which were all derived from a
single genomic locus, suggesting that there exists
only one gene encoding the iNOS. On the other hand,
w xBloch et al. 34 isolated at least three different iNOS
genes from two human genomic libraries, one of
which was consistent with, and the others were dif-
ferent from the previously described macrophage
iNOS. The diversity of Ca2qrcalmodulin dependency
w x9,12,31,35,36 exhibited by iNOSs from different
sources, and the different expression pattern of appar-
ently distinct iNOSs demonstrated in rat skeletal
w x w xmuscle 23 and kidney 37 may represent the exis-
 .tence of a novel iNOS isoform s . At present, how-
ever, it is unclear whether the minor differences of
the iNOS sequence observed here in the TNF-
arLPS-treated BAEC simply reflect species varia-
tion or individual polymorphism, or represent a dis-
tinct endothelial iNOS isoform. Interestingly, the re-
gion of human hepatocyte iNOS cDNA which corre-
sponded to the portion of BAEC iNOS sequenced in
this study includes a putative consensus sequence
 . w xRXS for phosphorylation 38 by cAMP-dependent
 .protein kinase Fig. 9 . The serine residue at the
phosphorylation site, however, is replaced for alanine
in BAEC iNOS, suggesting that the post-translational
regulation of NOS activity could also be different
among these iNOSs.
We also demonstrated that a different combination
of cytokinerLPS using IFN-a ,b instead of TNF-a
increased the Ca2q-dependent, membrane-associated
NOS activity, and the amount of ecNOS mRNA
whose sequence precisely matched with that of the
w xreported ecNOS cDNA. Rozenkranz-Weiss et al. 39
showed that the combination of TNF-a , IL-1b and
IFN-g increased the Ca2q-dependent ecNOS-like ac-
tivity in human umbilical vein endothelial cells, but
they ascribed the increase to that in tetrahydro-
 .biopterin THB availability through cytokine-media-
ted direct activation of biopterin synthetic enzymes.
The discrepancy of the time-dependent changes of
the enzyme activity and the mRNA levels of ecNOS
 .Figs. 2 and 6 may also suggest the involvement of
post-transcriptional or post-translational regulation of
ecNOS by cytokinerLPS treatment. A nuclear run-on
assay and a suppression experiment by actinomycin
D, however, indicated that the increase of ecNOS
observed in the IFN-a ,brLPS-treated BAEC was at
least in part attributed to the transcriptional activation
of ecNOS gene. The present results, therefore, indi-
( )Y. Kaku et al.rBiochimica et Biophysica Acta 1356 1997 43–52 51
cated that the ecNOS of BAEC could also be in-
ducibly expressed by the stimulation of IFN-
a ,brLPS in addition to the basal constitutive expres-
sion.
w xRecently, genomic clones of iNOS 40–42 and
w x XecNOS 43,44 were isolated. The 5 -flanking region
of the iNOS gene had several consensus sequences of
putative regulatory elements which involved in a
w xtranscriptional regulation of iNOS mRNA 40–42 .
These consensus sequences include NF-k B and TNF
response elements which were reported to be acti-
vated by LPS and TNF-a , respectively, and thus
probably are responsible for the TNF-arLPS-media-
ted expression of iNOS mRNA observed in this
study. Although different combinations of LPS and
cytokines seemed to be required for iNOS induction
w xin different cell types 15,45,46 , the exact mecha-
nism of the cell-type specific control of iNOS expres-
sion remained unknown.
w x XThe reported sequence 43,44 of the 5 -flanking
region of the ecNOS gene contained several putative
cis-acting elements which were potentially regulated
 .by AP-1 JunrFos , NF-1, cAMP, heavy metal, shear
stress and sterol, but lacked regulatory elements re-
sponsible for LPS andror cytokine-associated regula-
tions. The apparent increase of ecNOS mRNA in
IFN-a ,brLPS-treated BAEC observed in the present
study, therefore, could be mediated through a post-
transcriptional control such as stabilization of mRNA,
or indirect activation of one of the above regulatory
elements by IFNrLPS-triggered signals. Miura et al.
w x47 , proposed the possibility that the signal through
JAK tyrosine kinase which is known to be activated
by various cytokines including interferones could
lead to AP-1 activation via cross-talk signaling of
JAK kinase to Ras-MAP kinase pathway.
Accumulating evidence demonstrated that the co-
expression of multiple isoforms of NOS including
 .iNOS s , ecNOS and nNOS in several tissues
w x23,27,45,46 . Some cells like BAEC in this study
co-expressed multiple isoforms within a single cell.
Although the pathophysiological significance of dis-
tinct NOS isoforms co-expressed in restricted area is
still unknown, it has been suggested that ecNOS and
nNOS co-expressed in muscle fiber may play novel
roles in the regulation of muscle contraction,
oxygen-mediated cell damage, and oxidative energy
w xmetabolism 23,48 .
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